198 related articles for article (PubMed ID: 22308267)
41. Bryostatin 5 induces apoptosis in acute monocytic leukemia cells by activating PUMA and caspases.
Wang Y; Zhang J; Wang Q; Zhang T; Yang Y; Yi Y; Gao G; Dong H; Zhu H; Li Y; Lin H; Tang H; Chen X
Eur J Pharmacol; 2013 Oct; 718(1-3):340-9. PubMed ID: 24036350
[TBL] [Abstract][Full Text] [Related]
42. Differential effect of bryostatin 1 and phorbol 12-myristate 13-acetate on HOP-92 cell proliferation is mediated by down-regulation of protein kinase Cdelta.
Choi SH; Hyman T; Blumberg PM
Cancer Res; 2006 Jul; 66(14):7261-9. PubMed ID: 16849575
[TBL] [Abstract][Full Text] [Related]
43. Comparison of the antitumor activity of bryostatins 1, 5, and 8.
Kraft AS; Woodley S; Pettit GR; Gao F; Coll JC; Wagner F
Cancer Chemother Pharmacol; 1996; 37(3):271-8. PubMed ID: 8529289
[TBL] [Abstract][Full Text] [Related]
44. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity.
Hornung RL; Pearson JW; Beckwith M; Longo DL
Cancer Res; 1992 Jan; 52(1):101-7. PubMed ID: 1727368
[TBL] [Abstract][Full Text] [Related]
45. Enhancement of cisplatin sensitivity of cisplatin-resistant human cervical carcinoma cells by bryostatin 1.
Mohanty S; Huang J; Basu A
Clin Cancer Res; 2005 Sep; 11(18):6730-7. PubMed ID: 16166454
[TBL] [Abstract][Full Text] [Related]
46. Delta-protein kinase C phosphorylation parallels inhibition of nerve growth factor-induced differentiation independent of changes in Trk A and MAP kinase signalling in PC12 cells.
Wooten MW; Seibenhener ML; Heikkila JE; Mischak H
Cell Signal; 1998 Apr; 10(4):265-76. PubMed ID: 9617484
[TBL] [Abstract][Full Text] [Related]
47. Bryostatin-5 blocks stromal cell-derived factor-1 induced chemotaxis via desensitization and down-regulation of cell surface CXCR4 receptors.
He X; Fang L; Wang J; Yi Y; Zhang S; Xie X
Cancer Res; 2008 Nov; 68(21):8678-86. PubMed ID: 18974109
[TBL] [Abstract][Full Text] [Related]
48. STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1.
Battle TE; Frank DA
Blood; 2003 Oct; 102(8):3016-24. PubMed ID: 12855573
[TBL] [Abstract][Full Text] [Related]
49. Biological activity of 26-succinylbryostatin 1.
Bignami GS; Wagner F; Grothaus PG; Rustagi P; Davis DE; Kraft AS
Biochim Biophys Acta; 1996 Jul; 1312(3):197-206. PubMed ID: 8703988
[TBL] [Abstract][Full Text] [Related]
50. Potentiation of ara-C-induced apoptosis by the protein kinase C activator bryostatin 1 in human leukemia cells (HL-60) involves a process dependent upon c-Myc.
Chelliah J; Freemerman AJ; Wu-Pong S; Jarvis WD; Grant S
Biochem Pharmacol; 1997 Sep; 54(5):563-73. PubMed ID: 9337072
[TBL] [Abstract][Full Text] [Related]
51. Simplified Bryostatin Analogues Protect Cells from Chikungunya Virus-Induced Cell Death.
Staveness D; Abdelnabi R; Schrier AJ; Loy BA; Verma VA; DeChristopher BA; Near KE; Neyts J; Delang L; Leyssen P; Wender PA
J Nat Prod; 2016 Apr; 79(4):675-9. PubMed ID: 26900625
[TBL] [Abstract][Full Text] [Related]
52. New approaches to the total synthesis of the bryostatin antitumor macrolides.
Hale KJ; Manaviazar S
Chem Asian J; 2010 Apr; 5(4):704-54. PubMed ID: 20354984
[TBL] [Abstract][Full Text] [Related]
53. p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: In vitro versus in vivo activity.
Wang H; Mohammad RM; Werdell J; Shekhar PV
Int J Mol Med; 1998 Jun; 1(6):915-23. PubMed ID: 9852625
[TBL] [Abstract][Full Text] [Related]
54. Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency.
Pérez M; de Vinuesa AG; Sanchez-Duffhues G; Marquez N; Bellido ML; Muñoz-Fernandez MA; Moreno S; Castor TP; Calzado MA; Muñoz E
Curr HIV Res; 2010 Sep; 8(6):418-29. PubMed ID: 20636281
[TBL] [Abstract][Full Text] [Related]
55. Biological activity of the bryostatin analog Merle 23 on mouse epidermal cells and mouse skin.
Kelsey JS; Cataisson C; Chen J; Herrmann MA; Petersen ME; Baumann DO; McGowan KM; Yuspa SH; Keck GE; Blumberg PM
Mol Carcinog; 2016 Dec; 55(12):2183-2195. PubMed ID: 26859836
[TBL] [Abstract][Full Text] [Related]
56. Triptonide acts as a novel potent anti-lymphoma agent with low toxicity mainly through inhibition of proto-oncogene Lyn transcription and suppression of Lyn signal pathway.
Yang P; Dong F; Zhou Q
Toxicol Lett; 2017 Aug; 278():9-17. PubMed ID: 28666825
[TBL] [Abstract][Full Text] [Related]
57. The rational design of potential chemotherapeutic agents: synthesis of bryostatin analogues.
Wender PA; Hinkle KW; Koehler MF; Lippa B
Med Res Rev; 1999 Sep; 19(5):388-407. PubMed ID: 10502742
[TBL] [Abstract][Full Text] [Related]
58. Challenges to the development of bryostatin-type anticancer drugs based on the activation mechanism of protein kinase Cδ.
Irie K; Yanagita RC; Nakagawa Y
Med Res Rev; 2012 May; 32(3):518-35. PubMed ID: 22539107
[TBL] [Abstract][Full Text] [Related]
59. The practical synthesis of a novel and highly potent analogue of bryostatin.
Wender PA; Baryza JL; Bennett CE; Bi FC; Brenner SE; Clarke MO; Horan JC; Kan C; Lacôte E; Lippa B; Nell PG; Turner TM
J Am Chem Soc; 2002 Nov; 124(46):13648-9. PubMed ID: 12431074
[TBL] [Abstract][Full Text] [Related]
60. Divergent effects of bryostatin 1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937).
Vrana JA; Saunders AM; Chellappan SP; Grant S
Differentiation; 1998 May; 63(1):33-42. PubMed ID: 9615391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
